Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
 |
 |
 |
|
||
 |
|
 |
|
||
news
January 11, 2012
Napo Secures Dismissal of Legal Action.pdf
Napo Secures Dismissal of Legal Action.pdf
November 10, 2011
Napo Terminates Salix for Breach of Agreement For Failure to Commercially Develop Crofelemer
Napo Terminates Salix for Breach of Agreement For Failure to Commercially Develop Crofelemer
October 11, 2011
Annual Meeting Results
Annual Meeting Results
May 16, 2011
Dennis Fenton, Ph.D. to Join Board of Napo Pharmaceuticals, Inc.
Dennis Fenton, Ph.D. to Join Board of Napo Pharmaceuticals, Inc.
April 4, 2011
Napo to Present at Key Conference in China
Napo to Present at Key Conference in China
March 28, 2011
Appointment of Neelam Sekhri Feachem as Senior Vice President, Global Access and Alliances
Appointment of Neelam Sekhri Feachem as Senior Vice President, Global Access and Alliances
February 14, 2011
Napo Announces Successful Treatment of Adult Acute Watery Diarrhea
Napo Announces Successful Treatment of Adult Acute Watery Diarrhea
December 30, 2010
Napo CEO Lisa Conte Featured in Forbes Magazine
Napo CEO Lisa Conte Featured in Forbes Magazine
November 4, 2010
Crofelemer Demonstrates Highly Statistically Significant Results in
the Treatment of Chronic Diarrhea in People Living with
HIV/AIDS
Crofelemer Demonstrates Highly Statistically Significant Results in the Treatment of Chronic Diarrhea in People Living with HIV/AIDS
October 26, 2010
Letter to Shareholders
Letter to Shareholders
April 20, 2010
Napo Enters Finder's Agreement for Development of Crofelemer in China
Napo Enters Finder's Agreement for Development of Crofelemer in China
October 26, 2009
Napo Acquires Rights to Additional CFTR Technology
Napo Acquires Rights to Additional CFTR Technology
October 8, 2009
Napo Gathers International Panel on Global Health
Napo Gathers International Panel on Global Health
August 4, 2009
Napo Pharmaceuticals Completes Dose Selection Phase of ADVENT Trial
Napo Pharmaceuticals Completes Dose Selection Phase of ADVENT Trial
May 31, 2009
KRON 4 - Napo Pharmaceuticals, Inc. Interview
KRON 4 - Napo Pharmaceuticals, Inc. Interview
May 27, 2009
Napo Participation in Call to Action to Prevent Deaths from Diarrheal Diseases in Children Under Five Years of Age
Napo Participation in Call to Action to Prevent Deaths from Diarrheal Diseases in Children Under Five Years of Age
May 19, 2009
Napo Pharmaceuticals, Inc. Appoints New Vice-President of Business Development
Napo Pharmaceuticals, Inc. Appoints New Vice-President of Business Development
May 5, 2009
Napo Pharmaceuticals Initiates Preclinical Development of a Novel CFTR Inhibitor Using Preclinical Resources Offered by the National Institute of Allergy and Infectious Diseases (NIAID)
Napo Pharmaceuticals Initiates Preclinical Development of a Novel CFTR Inhibitor Using Preclinical Resources Offered by the National Institute of Allergy and Infectious Diseases (NIAID)
April 30, 2009
Napo Pharmaceuticals Receives Biotech Humanitarian Award Nomination
Napo Pharmaceuticals Receives Biotech Humanitarian Award Nomination